Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | Bidimentional liquid biopsy analysis

Umberto Malapelle • 18 Oct 2022
ISLB 2022
General

Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, talks on the importance of combining different approaches in liquid biopsy to improve specificity and sensitivity, and explains how to analyse both DNA and RNA in a bidimentional liquid biopsy analysis. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Speaker’s bureau for Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, BMS, Thermofisher, Biocartis.
Advisory role for Boehringer Ingelheim, MSD, Amgen, Merck, BMS, Diaceutics, Roche, Eli Lilly, Thermofisher, Janssen.

More from Umberto Malapelle

How will liquid biopsies improve early detection of lung cancer?
1:03
How will liquid biopsies improve early detection of lung cancer?
Umberto Malapelle • 9 Sep 2024
Recommendations for reporting NGS results in NSCLC
0:48
Recommendations for reporting NGS results in NSCLC
Umberto Malapelle • 9 Sep 2024
Tissue and liquid biopsy concordance in detecting EGFR mutations in NSCLC
0:51
Tissue and liquid biopsy concordance in detecting EGFR mutations in NSCLC
Umberto Malapelle • 9 Sep 2024
Real-world clinical and molecular NSCLC data in Biomarkers ATLAS
0:48
Real-world clinical and molecular NSCLC data in Biomarkers ATLAS
Umberto Malapelle • 9 Sep 2024

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals